AzTrials
AzTrials

Fibromyalgia (FM)NCT05230602

Consuming of Opuntia Among Women With Fibromyalgia

A study testing opuntia (tzabar fruit) in people with Fibromyalgia (FM), run by Soroka University Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To examine whether the addition of tzabar fruit twice a day to a routine daily nutrition regime will: A- Reduce symptoms of fatigue, pain and depression in FM patients B. Have positive influence on quality of life Read more about this study

Who is it for?
Ages 18 to 120 years, women only
Conditions the study is for
Fibromyalgia (FM)
What is being tested?
opuntia (tzabar fruit)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
1 siteIsrael
Study dates
1 Jun 2022to 1 Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • women diagnosed with FM
  • Age over 18
  • Fluent in Hebrew

Who cannot join

  • sensitivity to tzabar/exotic fruits
  • Suffer from digestive issues, such as irritable bowel syndrome
  • Participating in another interventional study
  • Removal criteria
  • Participants who do not complete the study follow-up period.

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Soroka Medical Center

    Beersheba, Southern District, 151

Other trials in Israel

About this study

Official title: Can a Daily Consuming of Opuntia (Tzabar Fruit) Reduce Symptoms of Fatigue, Pain and Depression Among Women With Fibromyalgia

To examine whether the addition of tzabar fruit twice a day to a routine daily nutrition regime will:

A- Reduce symptoms of fatigue, pain and depression in FM patients

  1. Have positive influence on quality of life
Read the detailed description

Project description Fibromyalgia (FM) is a chronic and idiopathic syndrome, characterized by a general distributed pain, more prevalent in women. Alongside with musculoskeletal pain, symptoms of fatigue, depression, anxiety and cognitive dysfunction are reported by the patients .The underlying pathophysiology of FM is still poorly understood, and treatment is often unsatisfactory. Current research provides evidence for altered pain processing in chronic pain patients, and specifically in FM patients.

Treatment for this syndrome is challenging and focuses on alleviation of symptoms. Patients use prescribed medication together with different complementary and alternative medicine treatments. Yet, the lack of adherence to the established treatment is quite common. Some patients do not conform to prescribed medication and reduce the recommended dose or interrupt the treatment whereas others use overdoses and self-medication. It is important to note that the patient's quality of life was higher in patients with higher adherence to treatment and persistence. Due to the lack of specific and standardized treatments for the management of FM, available evidence suggests a multidisciplinary approach, and nutrition represents an important therapeutic strategy.

The rationale for the current study is based on the platform of other chronic disease and the beneficial effect of consuming opuntia fruits (tzabar). The investigators propose a change in diet to reduce fatigue and chronic pain.

The mechanism explaining the benefits of opuntia fruit-tzabar, are not fully clear. Yet, several proposed pathways are suggested in the literature. The effect of tzabar was studied in in vitro model by Nunes et al. (2011) using intestinal cells taken from patients with Crohn and Colitis. Nunes et al. (2011) found that tzabar extract reduced pro-inflammatory mediators' secretion of IL-8. The reduction of IL-8 was explained via the reduction of NFkB pathway activation. This pathway inhibits the nuclear translocation of the redox sensitive transcription factor NFkB. Another possible mechanism for alleviation of pain symptoms is the high percentages of polysaccharides that tzabar fruits contain. High levels of polysaccharides were related to inhibition of alpha glucosidase inhibitor through a barrier function. Furthermore, tzabar has high level of fibers such as pectin which are beneficial to a healthy diet regime.

The investigators will examine whether an addition of tzabar twice a day to a daily nutrition regime will reduce the symptoms of fatigue and pain among patients with FM.

Aims

  1. To examine whether the consumption of tzabar fruit has a positive influence on the reduction of fatigue, pain and depressive symptoms among patients with FM.
  2. To examine whether the consumption of tzabar fruit has a positive influence on quality of life of patients with FM.

Hypotheses

  1. The consumption of tzabar fruit twice a day for one month will reduce symptoms of a) fatigue, b) pain and c) depression among patients with FM.
  2. The consumption tzabar fruit twice a day for one month will have a beneficial influence on the quality of life of FM patients.

Method Longitudinal study design. Inclusion criteria are women diagnosed with FM, age over 18, fluent in Hebrew. Non-inclusion criteria are FM patients with known sensitivity to tzabar/exotic fruits, FM patients known to suffer from digestive issues, such as irritable bowel syndrome, FM patients participating in another interventional study. Removal criteria are participants who do not complete the study follow-up period. The patients will be recruited from the rheumatological clinic at the Soroka Medical Center. Each patient arriving at the clinic and answering the inclusion criteria will be invited to participate and will sign an informed consent. The clinic operated once a week. Patients arriving on even dates during the first month of the study will be entered to the study group whereas patients on odd dates will comprise the control group.

The investigators performed calculations to estimate sample size. The investigators expected a modest (2.9 points on a 10-point scale) reduction in pain, relative to control. Given previously reported SDs of 3.5 on this scale in fibromyalgia, following Rasmussen et al. (2012) the sample size needed to detect an effect of this size, with a two-tailed alpha of 0.05 and power of 0.80, was 15 per group.

Measurement Dependent variables (quality of life, anxiety, pain, fatigue, depression) will be measured using the Widespread Pain Index (WPI), and the Symptom Severity Scale (SSS), along with Hebrew version of the quality-of-life questionnaire SF-36. Depression will be assessed by Beck Depression Inventory. Those that will be detected with depression will be refer back to Dr. Zeler for advice and treatment. If needed the psychiatric ward will be informed to build treatment program.

Process At the start of the study (T1), the participants will fill the above scales. The participants will then be divided randomly into two equal groups. Group A will be instructed to eat the tzabar fruit twice a day for two weeks, while Group B, the control group, will be instructed not to change their diet. At the end of 14 days (T2) all participants will be re-assessed again. Then Group B will be instructed to eat the tzabar fruit twice a day for 14 days, while Group A, will be instructed to eat their regular diet. During the research period, the participants will be instructed to continue their regular treatment routine, whether this includes taking medication, performing sporting activity, and so on in order to avoid undesirable influences that could bias the research results. The tzabar fruits will be supplied by the research team, in a neutral location. After a month all participants will fill the above scales.

Statistical analysis of data The statistical analysis of the data will be conducted using SPSS software. Descriptive statistics will be employed to characterize the sample. The data will be presented as categorical, ordinal, or continuous variables. For categorical variables, the number of participants and the percentage in each category will be presented. Ordinal variables will be presented using the median and the frequent. Quantitative variables will be presented using the average and standard deviation values. The changes in QOL and fatigue measures in each study group during the follow-up period will be analyzed with two-way repeated measures ANOVA, and comparison between the group will be performed using MANOVA. Multivariate analysis will include General Linear Model (GLM) for each outcome. The independent variables will include the study group, study period, interaction variable (study group * period) and the baseline characteristics of the patients. The effect of mediation (SABRES - fatigue - QOL) will be analyzed with SOBEL test.

Being tested
opuntia (tzabar fruit)
Medical subject headings
Fibromyalgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • opuntia (tzabar fruit)Dietary supplement

    consuming of the tzabar fruit twice a day

Study groups in NCT05230602
Study groupRoleWhat they receive
Study GroupExperimentalThe participants will fill the study scales and will be instructed to eat the tzabar fruit twice a day for two weeks
Receives: Dietary Supplement: opuntia (tzabar fruit)
Control GroupNo interventionThe participants will fill the study scales and will be instructed not to change their diet for two weeks

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. consumption of tzabar fruit has a positive influence on the reduction of pain

    Pain will be measured using the Widespread Pain Index (WPI) higher scores indicate greater widespread pain

    Measured: Two weeks

  2. consumption of tzabar fruit has a positive influence on fatigue

    fatigue will be measured using the Symptom Severity Scale (SSS) (Wolfe et al.,2010). higher scores indicate severe Symptoms including fatigue

    Measured: Two weeks

  3. consumption of tzabar fruit has a positive influence on fatigue

    fatigue will be measured using the Hebrew version of the quality-of-life questionnaire SF-36 (Levin-Epstein et al., 1998) higher scores indicate beter QOL and less fatigue

    Measured: Two weeks

  4. consumption of tzabar fruit has a positive influence on depressive symptoms

    Depression will be assessed by Beck Depression Inventory (Beck, 1996). higher scores indicate severe depressive symptoms.Those that will be detected with depression will be refer back to the outpatient clinic for advice and treatment

    Measured: Two weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2022
  2. Study start1 Jun 2022
  3. Primary completion1 Jun 2024 (estimated)
  4. Study completion1 Jun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
At the start of the study (T1), the participants will fill the above scales. The participants will then be divided randomly into two equal groups. Group A will be instructed to eat the tzabar fruit twice a day for two weeks, while Group B, the control group, will be instructed not to change their diet. At the end of 14 days (T2) all participants will be re-assessed again. Then Group B will be instructed to eat the tzabar fruit twice a day for 14 days, while Group A, will be instructed to eat their regular diet. During the research period, the participants will be instructed to continue their regular treatment routine, whether this includes taking medication, performing sporting activity, and so on in order to avoid undesirable influences that could bias the research results. The tzabar fruits will be supplied by the research team, in a neutral location. After a month all participants will fill the above scales.
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05230602
Sponsor's protocol ID
0207-21-SOR
Status last verified
Dec 2022
First submitted
14 Dec 2021
Last updated
14 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing opuntia (tzabar fruit) in people with Fibromyalgia (FM), run by Soroka University Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

consumption of tzabar fruit has a positive influence on the reduction of pain (time frame: Two weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in